Navigation Links
Hemostemix Announces US Patent Allowance
Date:6/5/2013

Kyriat Weizmann, Israel (PRWEB) June 05, 2013

Hemostemix, Ltd. (“Hemostemix”, the “Company”) announced today the issuance of a Notice of Allowance from the United States Patent and Trademark Office for a patent entitled “A Composition Comprising A Progenitor/Precursor Cell Population”.

The patent pertains to a population of cultured cells which meet certain criteria and constitute the foundation of the Company’s angiogenic (blood vessel growing) technology. The product developed on the basis of this technological platform will be used in a Phase 2 clinical trial for critical limb ischemia. The trial protocol was recently cleared by Health Canada and the trial is expected to commence later this year.

This patent is part of a broad technology platform now protected by 38 patents issued in major markets, such as the US, EU, Japan and China. The company continues to aggressively file and prosecute patents around all aspects of its technology as an important foundation for its global commercialization plans.

“The cell population which is the subject of this patent,” stated Hemostemix’ President, Dr. Valentin Fulga, “is an important pillar of our technology. This cell population is generated from a core population of cells we named Synergetic Cell Population (“SCP”), which is isolated from a simple blood collection. We believe the SCP not only has the potential to differentiate into blood vessels, but can also be transformed, through proprietary cell-culturing techniques, into other cell types, such as cardiomyocyte-like cells and neural cells.”

About Hemostemix Ltd

Hemostemix Ltd is a company incorporated in Israel with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. Hemostemix and Kwalata Trading Ltd (“Kwalata”), registered in Cyprus, are wholly-owned subsidiaries of Canadian-based parent company, Theravitae Inc (“TVI”) (together the “Hemostemix Group”). Kwalata holds the intellectual property on behalf of the Hemostemix Group. On 14 May 2013, TVI announced a letter of intent signed with Technical Ventures RX Corp (TSX-V:TIK.P) ("Technical") regarding a proposed Qualifying Transaction in which Technical would acquire TVI and its subsidiaries in a share transaction. For more information see http://www.hemostemix.com.

Read the full story at http://www.prweb.com/releases/2013Hemostemix/USPTOallowance/prweb10777870.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. The Hemostemix Group of Companies Provides Corporate Strategy Update
2. Array BioPharma Announces Pricing of Public Offering of $115 Million of Convertible Senior Notes
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Arteriocyte announces Launch of Compass Biomedical
5. TNI BioTech, Inc. Announces Death of Senior Vice President and Chief Medical Officer, Dr. Ronald Herberman
6. Elsevier Announces its Collaboration with Kasetsart University, Thailand
7. Celsion Corporation Announces $9.83 Million Registered Direct Offering
8. Caris Life Sciences Announces Planned Expansion of Next-Generation Sequencing (NGS) Capabilities
9. 3SBio Inc. Announces Completion of Merger
10. AtheroNova Announces Shipment of Phase 1 Drug Product
11. The Sidney Kimmel Foundation for Cancer Research Announces 2013 Grant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , ... May 03, 2016 , ... In a list ... out of the state’s 76 fastest-growing private companies; a small percentage of the state's ... ranked organizations on the percent change in revenue from 2012 to 2015. ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... addition of Dr. Nancy Gillett to its Board of Directors. Dr. Gillett recently ... as Corporate Executive Vice President and Chief Scientific Officer. A board-certified veterinary pathologist, ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... NeuroTech NYC , the sensor and data driven conferences, will take place on June 7-8, ... UnitedHealth's Vidya Raman-Tangella on incorporating technology -- including AR/VR, machine learning, ...
(Date:5/3/2016)... May 3, 2016  Dr. Thomas P. McHugh ... The Woodlands, Texas , now offers ... of treated fat cells in just 25-minutes, leaving a ... 90 percent of Americans report feeling bothered by excess ... reduction procedures are a growing industry. This innovative new ...
Breaking Biology Technology:
(Date:3/11/2016)... 2016 http://www.apimages.com ) - --> ... available at AP Images ( http://www.apimages.com ) - ... to produce the new refugee identity cards. DERMALOG will be unveiling ... in Hanover next week.   --> ... used to produce the new refugee identity cards. DERMALOG will be ...
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
(Date:3/3/2016)... and DE SOTO, Kansas , ... Stroke Detection Plus® to offer Oncimmune,s Early CDT®-Lung, ... and early detection of lung cancer Early ... unions and individuals. --> Early CDT®-Lung test ... individuals. --> Oncimmune, a leader in early ...
Breaking Biology News(10 mins):